Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
about
Cytochrome P-450 isozyme pattern is related to individual susceptibility to diethylnitrosamine-induced liver cancer in ratsRelationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration.Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosisAccuracy and clinical utility of simplified tests of antipyrine metabolismGenetic variation in rates of antipyrine metabolite formation: a study in uninduced twinsMonogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition.Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors.Disposition of hexobarbital: 15 years of an intriguing model substrate.Human cytochromes P-450.Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat.A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.Differential effects of enzyme induction on antipyrine metabolite formation.Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.Effect of pregnenolone carbonitrile, promethazine and antipyrine pretreatment on antipyrine metabolite formation in rats.Quantitation and urinary pattern of 4,4'-dihydroxy-antipyrine, 4-hydroxy-antipyrine and 3-hydroxymethyl-antipyrine, as main metabolites of antipyrine in man and rat.Inhibition of antipyrine metabolite formation in rats in vivo.Influence of 9-hydroxyellipticine and 3-methylcholanthrene treatment on antipyrine metabolite formation in rats in vivo.Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats.Inhibition of antipyrine metabolism by beta-adrenoceptor antagonistsStudies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.Hypotensive and sedative properties of alpha-adrenoceptor agonists: relation to pre- and post-synaptic stimulation [proceedings]Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.Influence of liver damage on antipyrine metabolite formation in rats.Incidence of a subclinical fascioliasis on antipyrine clearance and metabolite excretion in sheep.Metabolism of metronidazole and antipyrine in hepatocytes isolated from mouse and rat.Demonstration of H2O2 production in vivo during aminopyrine metabolism and phenobarbital induction.Metabolism of antipyrine and sulphadimidine in dwarf goats: effects of the enzyme-inducing agents phenobarbital, troleandomycin and rifampicin.The effect of midazolam administration on the pharmacokinetics of antipyrine in the rat.Correlation between the metabolism of hexobarbital and aminopyrine in vivo in rats.
P2860
Q28326998-8FEDECF2-A331-4891-8B90-89806D0203DFQ34418061-70FEAE41-4BC7-4990-999E-2B2AF3C5F3A4Q34449586-AEC8BCA8-979F-41B5-909E-CB4438DD4484Q34512413-A62FEFA8-AD48-4DD6-BB23-350E730F6757Q34621602-D82A1135-6FB2-4D1B-A919-0FFFF1E35A84Q34621803-641DB7C2-547D-499C-B7A0-41A97CC860C7Q35469675-F67C249F-CE40-4808-8B5A-0F8BD85EC13AQ36989899-8A28774B-4232-4C82-8B67-29B8473E9988Q37913362-D09F2312-1A37-4BA6-A6C7-36B0B2F9A5A7Q38023212-1EC7841B-5841-4848-ADED-F0E2ADA1AF56Q39567059-AAAC652A-5EA3-4441-A44B-7AEA2869DFC9Q40176472-6EFD36FF-1EF2-41C3-9639-72F1B7A05AC5Q41747906-93C63164-B344-47F2-890A-4A1F2E0F5A1EQ41974281-31C9A796-931D-4C57-B21A-948D6AA1EEFCQ42017833-1A217238-4288-4BFB-A477-EEB72E0AFF34Q42021525-604E3FD2-D184-4A3C-8C54-8C22BD62A57BQ42040905-22EAF6F5-12C7-43DD-A58D-64B5B809A500Q42223320-C65195B6-7FE7-439C-B10C-23300E8F9B80Q42241495-C6E1D218-94DF-4A0C-B860-F9D856524056Q42251069-AE1AD4A2-D218-47B8-9EA6-C4F2C63FE342Q42253305-9626F558-46B6-4A95-8873-FF799F3CD512Q42254208-F6E97F08-05D7-4AC9-AA33-C9984B001E32Q42285279-5305F569-86D6-4168-8BAD-6A9D154F4B1DQ42285318-036C2500-A149-4E64-880E-F4673F11D230Q42631792-6537CE5C-F9B9-409C-8F06-BC66116FB485Q43240294-4EE9C0C2-918A-497D-8D37-18054245935EQ43429348-0CA77F11-BF98-462F-9F76-B3DC70B12CB8Q44673368-D555859B-12DC-478F-AB4F-6B41E8657A6CQ45005065-104ED43A-DF68-4C02-87BB-397AE767F6B1Q46604724-A54C6EDA-85CB-4D9D-9051-BD179012697CQ46801997-289D2137-2650-4D96-8321-FE601AC32839Q51788073-A2D81CCE-4074-4DFE-BD9B-A26B6C3A1814Q54189506-EDCEB50C-22E7-426F-9569-BB6367FEFD6D
P2860
Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年学术文章
@wuu
1979年学术文章
@zh-cn
1979年学术文章
@zh-hans
1979年学术文章
@zh-my
1979年学术文章
@zh-sg
1979年學術文章
@yue
1979年學術文章
@zh
1979年學術文章
@zh-hant
name
Studies on the different metab ...... -methylcholanthrene treatment.
@en
Studies on the different metab ...... -methylcholanthrene treatment.
@nl
type
label
Studies on the different metab ...... -methylcholanthrene treatment.
@en
Studies on the different metab ...... -methylcholanthrene treatment.
@nl
prefLabel
Studies on the different metab ...... -methylcholanthrene treatment.
@en
Studies on the different metab ...... -methylcholanthrene treatment.
@nl
P2093
P2860
P1433
P1476
Studies on the different metab ...... -methylcholanthrene treatment.
@en
P2093
P2860
P304
P356
10.3109/00498257909042337
P407
P577
1979-11-01T00:00:00Z